New data supporting modified RECIST (mRECIST) for hepatocellular carcinoma

Riccardo Lencioni

doi:10.1158/1078-0432.CCR-12-3796

New data supporting modified RECIST (mRECIST) for hepatocellular carcinoma

Riccardo Lencioni

Radiology

Research output: Contribution to journal › Article › peer-review

68 Scopus citations

Abstract

The modified Response Evaluation Criteria in Solid Tumors (mRECIST) guideline has introduced specific amendments to standard RECIST to address the unique complexities involved in the evaluation of tumor response in hepatocellular carcinoma. A growing amount of data suggests that mRECIST, designed for response assessment in clinical trials, may translate into a tool for clinical practice.

Original language	English (US)
Pages (from-to)	1312-1314
Number of pages	3
Journal	Clinical Cancer Research
Volume	19
Issue number	6
DOIs	https://doi.org/10.1158/1078-0432.CCR-12-3796
State	Published - Mar 15 2013

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1158/1078-0432.CCR-12-3796

Cite this

@article{b5d5b4c8a86a4a2397b86fc798b5d958,

title = "New data supporting modified RECIST (mRECIST) for hepatocellular carcinoma",

abstract = "The modified Response Evaluation Criteria in Solid Tumors (mRECIST) guideline has introduced specific amendments to standard RECIST to address the unique complexities involved in the evaluation of tumor response in hepatocellular carcinoma. A growing amount of data suggests that mRECIST, designed for response assessment in clinical trials, may translate into a tool for clinical practice.",

author = "Riccardo Lencioni",

year = "2013",

month = mar,

day = "15",

doi = "10.1158/1078-0432.CCR-12-3796",

language = "English (US)",

volume = "19",

pages = "1312--1314",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "6",

}

TY - JOUR

T1 - New data supporting modified RECIST (mRECIST) for hepatocellular carcinoma

AU - Lencioni, Riccardo

PY - 2013/3/15

Y1 - 2013/3/15

N2 - The modified Response Evaluation Criteria in Solid Tumors (mRECIST) guideline has introduced specific amendments to standard RECIST to address the unique complexities involved in the evaluation of tumor response in hepatocellular carcinoma. A growing amount of data suggests that mRECIST, designed for response assessment in clinical trials, may translate into a tool for clinical practice.

AB - The modified Response Evaluation Criteria in Solid Tumors (mRECIST) guideline has introduced specific amendments to standard RECIST to address the unique complexities involved in the evaluation of tumor response in hepatocellular carcinoma. A growing amount of data suggests that mRECIST, designed for response assessment in clinical trials, may translate into a tool for clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=84875127097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875127097&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-12-3796

DO - 10.1158/1078-0432.CCR-12-3796

M3 - Article

C2 - 23382112

AN - SCOPUS:84875127097

VL - 19

SP - 1312

EP - 1314

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 6

ER -

New data supporting modified RECIST (mRECIST) for hepatocellular carcinoma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this